- Report
- March 2025
Global
From €4460EUR$4,900USD£3,788GBP
- Report
- September 2024
- 106 Pages
Global
From €5006EUR$5,500USD£4,252GBP
- Report
- January 2025
- 152 Pages
Global
From €2048EUR$2,250USD£1,739GBP
- Report
- March 2025
- 188 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 192 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- February 2025
- 100 Pages
Global
From €5416EUR$5,950USD£4,600GBP
- Report
- April 2025
- 73 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 207 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 462 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 217 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 92 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 383 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- September 2024
- 150 Pages
Global
From €4414EUR$4,850USD£3,749GBP
- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- February 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- March 2025
- 182 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- February 2025
- 185 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- February 2025
- 184 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- July 2024
- 185 Pages
Global
From €4096EUR$4,500USD£3,479GBP

Circulating Tumor DNA (ctDNA) is a type of genetic material found in the bloodstream of cancer patients. It is a valuable tool for cancer diagnosis, prognosis, and treatment. ctDNA can be used to detect the presence of cancer, identify the type of cancer, and monitor the progression of the disease. It can also be used to detect mutations in cancer cells, which can help guide treatment decisions.
ctDNA is a rapidly growing field in genomics, with many companies developing technologies to detect and analyze ctDNA. These companies are developing technologies such as next-generation sequencing, digital PCR, and microfluidics to detect and analyze ctDNA. Companies are also developing technologies to detect and analyze ctDNA in real-time, allowing for more accurate and timely diagnosis and treatment.
Some companies in the ctDNA market include Illumina, Thermo Fisher Scientific, QIAGEN, Bio-Rad Laboratories, and Guardant Health. Show Less Read more